• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部不明来源的鳞状细胞癌。

Head and neck squamous cell carcinoma from an unknown primary site.

机构信息

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.

出版信息

Am J Otolaryngol. 2011 Jul-Aug;32(4):286-90. doi: 10.1016/j.amjoto.2010.05.004. Epub 2010 Aug 17.

DOI:10.1016/j.amjoto.2010.05.004
PMID:20719404
Abstract

BACKGROUND

The purpose of this study is to present our experience treating patients with squamous cell carcinoma (SCC) from an unknown head and neck primary site and to determine whether a policy change eliminating the larynx and hypopharynx from the radiotherapy (RT) portals has impacted outcome.

METHODS

One hundred seventy-nine patients received definitive RT with or without a neck dissection for SCC from an unknown head and neck primary site. RT was delivered to the ipsilateral neck alone or both sides of the neck and, usually, the potential mucosal primary sites. The median mucosal dose was 5670 cGy. The median neck dose was 6500 cGy. One hundred nine patients (61%) received a planned neck dissection.

RESULTS

Mucosal control at 5 years was 92%. The mucosal control rate in patients with RT limited to the nasopharynx and oropharynx was 100%. The 5-year neck-control rates were as follows: N(1), 94%; N(2a), 98%; N(2b), 86%; N(2c), 86%; N(3), 57%; and overall, 81%. The 5-year cause-specific survival rates were as follows: N(1), 94%; N(2a), 88%; N(2b), 82%; N(2c), 71%; N(3), 48%; and overall, 73%. The 5-year overall survival rates were as follows: N(1), 50%; N(2a), 70%; N(2b), 59%; N(2c), 45%; N(3), 34%; and overall, 52%. Eleven patients (7%) developed severe complications.

CONCLUSION

RT alone or combined with neck dissection results in a high probability of cure with a low risk of severe complications. Eliminating the larynx and hypopharynx from the RT portals did not compromise outcome and likely reduces treatment toxicity.

摘要

背景

本研究旨在介绍我们治疗来自头颈部未知原发灶的鳞状细胞癌(SCC)患者的经验,并确定是否改变将喉和下咽排除在放射治疗(RT)野之外的治疗策略会影响治疗效果。

方法

179 例来自头颈部未知原发灶的 SCC 患者接受了根治性 RT 治疗,其中部分患者同时接受了颈部清扫术。RT 仅用于单侧颈部或双侧颈部和(通常)潜在的黏膜原发灶。黏膜中位剂量为 5670cGy,颈部中位剂量为 6500cGy。109 例(61%)患者接受了计划的颈部清扫术。

结果

5 年时黏膜控制率为 92%。接受 RT 限于鼻咽和口咽的患者黏膜控制率为 100%。5 年颈部控制率如下:N(1)区为 94%,N(2a)区为 98%,N(2b)区为 86%,N(2c)区为 86%,N(3)区为 57%,总体为 81%。5 年无病生存率如下:N(1)区为 94%,N(2a)区为 88%,N(2b)区为 82%,N(2c)区为 71%,N(3)区为 48%,总体为 73%。5 年总生存率如下:N(1)区为 50%,N(2a)区为 70%,N(2b)区为 59%,N(2c)区为 45%,N(3)区为 34%,总体为 52%。11 例(7%)患者发生严重并发症。

结论

RT 单独或联合颈部清扫术可获得较高的治愈率,且严重并发症风险较低。将喉和下咽排除在 RT 野之外并未影响治疗效果,可能还降低了治疗毒性。

相似文献

1
Head and neck squamous cell carcinoma from an unknown primary site.头颈部不明来源的鳞状细胞癌。
Am J Otolaryngol. 2011 Jul-Aug;32(4):286-90. doi: 10.1016/j.amjoto.2010.05.004. Epub 2010 Aug 17.
2
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.调强放疗治疗不明头颈部原发灶的颈部淋巴结转移鳞癌:MD 安德森癌症中心的结果和失败模式。
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1005-10. doi: 10.1016/j.ijrobp.2009.09.006. Epub 2010 Mar 6.
3
Neck lymph node metastases from an unknown primary tumor retrospective study and review of literature.不明原发肿瘤颈部淋巴结转移的回顾性研究及文献综述
Strahlenther Onkol. 2005 Jun;181(6):355-62. doi: 10.1007/s00066-005-1338-2.
4
Unknown primary head and neck cancer treated with intensity-modulated radiation therapy: to what extent the volume should be irradiated.头颈部不明原发灶癌采用调强放疗治疗:照射范围应多大。
Oral Oncol. 2009 Jun;45(6):474-9. doi: 10.1016/j.oraloncology.2008.06.006. Epub 2008 Sep 18.
5
Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.原发灶不明的颈部淋巴结转移癌的调强放疗:单中心经验。
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1866-71. doi: 10.1016/j.ijrobp.2011.02.031. Epub 2011 Apr 15.
6
[Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients].[头颈部原发灶不明的鳞状细胞癌的诊断与治疗。167例患者的调查]
Laryngorhinootologie. 2003 Sep;82(9):659-65. doi: 10.1055/s-2003-42687.
7
Initial experience with oropharynx-targeted radiation therapy for metastatic squamous cell carcinoma of unknown primary of the head and neck.头颈部不明原发灶转移性鳞状细胞癌的口咽靶向放疗初步经验。
Anticancer Res. 2014 Jan;34(1):243-8.
8
The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+.淋巴结转移对口腔、口咽、喉和下咽鳞状细胞癌治疗的影响:N0与N+的对比
Laryngoscope. 2005 Apr;115(4):629-39. doi: 10.1097/01.mlg.0000161338.54515.b1.
9
Squamous cell carcinoma from an unknown head and neck primary site: a "selective treatment" approach.原发部位不明的头颈部鳞状细胞癌:一种“选择性治疗”方法。
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1282-7. doi: 10.1001/archotol.133.12.1282.
10
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.头颈部鳞状细胞癌的调强放射治疗——爱荷华大学的经验
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21. doi: 10.1016/j.ijrobp.2005.02.025.

引用本文的文献

1
Cervical squamous cell carcinoma of unknown primary: Oncological outcomes and prognostic factors.原发灶不明的宫颈鳞状细胞癌:肿瘤学结局及预后因素
Front Oncol. 2022 Nov 14;12:1024414. doi: 10.3389/fonc.2022.1024414. eCollection 2022.
2
Factors Influencing the Outcome of Head and Neck Cancer of Unknown Primary (HNCUP).影响原发灶不明的头颈癌(HNCUP)预后的因素。
J Clin Med. 2022 May 10;11(10):2689. doi: 10.3390/jcm11102689.
3
Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
HPV 阴性和不明原发灶的晚期头颈部癌(CUP)中手术与辅助放(化)疗的时间间隔的相关性。
BMC Cancer. 2021 Nov 18;21(1):1236. doi: 10.1186/s12885-021-08885-3.
4
Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival.瑞典全国性头颈部原发灶不明癌症多中心研究:预后因素及治疗对生存的影响
Int Arch Otorhinolaryngol. 2021 Jul;25(3):e433-e442. doi: 10.1055/s-0040-1712106. Epub 2020 Sep 30.
5
Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era.原发灶不明的转移性宫颈淋巴结鳞状细胞癌:人乳头瘤病毒时代的管理
Front Oncol. 2020 Nov 10;10:593164. doi: 10.3389/fonc.2020.593164. eCollection 2020.
6
Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage.不明原发灶头颈鳞状细胞癌调强放射治疗后的失败模式:选择性淋巴结及黏膜剂量覆盖的意义
Adv Radiat Oncol. 2020 May 15;5(5):929-935. doi: 10.1016/j.adro.2020.04.025. eCollection 2020 Sep-Oct.
7
Radiotherapeutic management of cervical lymph node metastases from an unknown primary site - experiences from a large cohort treated with modern radiation techniques.原发灶不明的颈部淋巴结转移的放射治疗管理——采用现代放射技术治疗的大队列经验。
Radiat Oncol. 2020 Apr 15;15(1):80. doi: 10.1186/s13014-020-01529-z.
8
Significance of the Neutrophil-to-Lymphocyte Ratio in p16-Negative Squamous Cell Carcinoma of Unknown Primary in Head and Neck.中性粒细胞与淋巴细胞比值在头颈部原发性不明的p16阴性鳞状细胞癌中的意义
Front Oncol. 2020 Jan 29;10:39. doi: 10.3389/fonc.2020.00039. eCollection 2020.
9
Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.诊断为不明原发灶转移性颈部癌并接受调强放疗的患者的治疗结果。
Cancer. 2018 Apr 1;124(7):1415-1427. doi: 10.1002/cncr.31235. Epub 2018 Jan 16.
10
Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection.原发灶不明的头颈部癌的预后因素,包括人乳头瘤病毒感染的影响。
J Otolaryngol Head Neck Surg. 2017 Jun 10;46(1):45. doi: 10.1186/s40463-017-0223-1.